Dr. Dipenkumar Modi, M.D.
Claim this profileKarmanos Cancer Institute
Expert in Lymphoma
Studies Non-Hodgkin's Lymphoma
19 reported clinical trials
45 drugs studied
Area of expertise
1Lymphoma
Global LeaderStage IV
Stage III
HLA-A negative
2Non-Hodgkin's Lymphoma
Stage IV
Stage III
CD20 positive
Affiliated Hospitals
Clinical Trials Dipenkumar Modi, M.D. is currently running
Epcoritamab + GDP
for Non-Hodgkin's Lymphoma
Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Day 1, and dexamethasone 40 mg orally on Days 1 through 4. Epcoritamab will be administered subcutaneously (SC) on Days 1, 8, and 15. Patients will receive granulocyte colony stimulating factor (G-CSF) between Day 8 through Day 10 of each cycle of combination therapy. Patients will then undergo radiology imaging for disease assessment. Patients may proceed to SCT(autologous or allogeneic) or CAR T-cell therapy or epcoritamab monotherapy upon completion of Cycle 3 per investigator discretion. The rationale for subjects not proceeding to autoSCT or CAR T-cell therapy will be captured in the eCRFs. Patients who do not undergo SCT or CAR T-cell therapy may have the option to receive study treatment with epcoritamab monotherapy following completion of Cycle 3. Epcoritamab monotherapy will be offered to selected subjects who become ineligible to undergo SCT or CAR T-cell therapy (such as social situation, change in subject decision). The decision to offer epcoritamab monotherapy will be per investigator's discretion. However, subjects must have demonstrated a response to the combination therapy (partial remission or complete remission) per disease assessment scans prior to offering epcoritamab monotherapy. Epcoritamab monotherapy should begin 2 weeks following Cycle 3 Day 15. Monotherapy will consist of epcoritamab 48 mg administered subcutaneously on Days 1 and 15 of each 28 day cycle for Cycle 4 to Cycle 9 or until unacceptable toxicity, or disease progression per the Lugano Criteria.
Recruiting1 award Phase 2
Stem Cell Transplantation
for Leukemia
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.
Recruiting1 award Phase 2
More about Dipenkumar Modi, M.D.
Clinical Trial Related1 year of experience running clinical trials · Led 19 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Dipenkumar Modi, M.D. has experience with
- Rituximab
- Cyclophosphamide
- Brentuximab Vedotin
- Fludarabine
- Tacrolimus
- Mycophenolate Mofetil
Breakdown of trials Dipenkumar Modi, M.D. has run
Lymphoma
Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma
B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dipenkumar Modi, M.D. specialize in?
Dipenkumar Modi, M.D. focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Dipenkumar Modi, M.D. currently recruiting for clinical trials?
Yes, Dipenkumar Modi, M.D. is currently recruiting for 9 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Dipenkumar Modi, M.D. has studied deeply?
Yes, Dipenkumar Modi, M.D. has studied treatments such as Rituximab, Cyclophosphamide, Brentuximab Vedotin.
What is the best way to schedule an appointment with Dipenkumar Modi, M.D.?
Apply for one of the trials that Dipenkumar Modi, M.D. is conducting.
What is the office address of Dipenkumar Modi, M.D.?
The office of Dipenkumar Modi, M.D. is located at: Karmanos Cancer Institute, Detroit, Michigan 48201 United States. This is the address for their practice at the Karmanos Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.